Psychedelic Research Centre Psilocybe cyananescens

Study recruitment closed. Psilocybin in patients with fibromyalgia: Brain biomarkers of action (PsiloPain)

Chronic pain is one of the leading causes of disability worldwide. Fibromyalgia, a condition characterised by widespread chronic pain, remains poorly understood with limited options for treatment. Psilocybin may provide an opportunity to affect the personal impact of pain in people living with fibromyalgia, and here, we wish to better understand how it may work.

For this study, we recruited adults with fibromyalgia who were deemed eligible at screening will attend eight study visits over eight weeks. Participants received psilocybin at least once, with a dose up to 25mg. Across these eight visits, there were three magnetic resonance imaging (MRI) scans, six electrophoretogram (EEG) recordings, and a range of questionnaires and interviews. There will also be a remote follow-up period of six months following the final study visit.

Please note that Psilocybin is not a licenced drug or treatment for fibromyalgia and therefore cannot be prescribed.

We have completed this study and are no longer accepting applications. We will publish the results of the study in due course and post updates on this website.

For any enquiries please email